drugset / Trial / NCT05638776
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Phase 2
Completed
58 enrolled
Regend Therapeutics
China-Japan Friendship Hospital · collabRegend Therapeutics XLotus (Jiangxi) Co, Ltd. · collabShanghai East Hospital · collabShanghai Zhongshan Hospital · collabSouthwest Hospital, China · collabThe First Affiliated Hospital of Guangzhou Medical University · collabThe First Affiliated Hospital of Nanchang University · collabThe First Affiliated Hospital of Soochow University · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.
Timeline
- Start
- 2022-12-06
- Primary completion
- 2025-07-09
- Completion
- 2025-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGEND001 | Cell therapy | — | — |